Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

588.15 +2.47 (+0.42%)
Official Closing Price Updated: 7:00 PM EST, Dec 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,157,129
Open 583.28
Bid (Size) 589.00 (11)
Ask (Size) 590.50 (1)
Prev. Close 585.68
Today's Range 579.37 - 591.80
52wk Range 302.14 - 629.97
Shares Outstanding N/A
Dividend Yield 0.77%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
Via Benzinga
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Weight-loss drugs such as Ozempic and Mounjaro are the leading blockbusters for a new epidemic 
Via Benzinga

Performance

YTD
+61.14%
+61.14%
1 Month
-1.18%
-1.18%
3 Month
+5.37%
+5.37%
6 Month
+29.57%
+29.57%
1 Year
+59.27%
+59.27%

More News

Read More
What the Options Market Tells Us About Eli Lilly
Via Benzinga
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
Via Investor's Business Daily
Ozempic vs. Mounjaro:: Battle of the bulge
Via MarketBeat
Exposures Product Safety
1 Monster Dividend Stock Growth Investors Should Load Up On Right Now
Via The Motley Fool
If You Invested $100 In This Stock 10 Years Ago, You Would Have $1,200 Today
Via Benzinga
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
Via The Motley Fool
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
Via MarketBeat
Topics Bonds
Exposures Debt Markets
FDA Grants Second Conditional Approval For Eli Lilly's Rare Blood Cancer Drug
Via Benzinga
Exposures Product Safety
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
Via Benzinga
3 No-Brainer Growth Stocks to Buy in December
Via The Motley Fool
Pfizer Tumbles After Abandoning Weight-Loss Pill
Via Talk Markets
An Important History Lesson for Gene-Editing Investors
Via The Motley Fool
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
Via The Motley Fool
5 Top Stocks to Buy Before 2024
Via The Motley Fool
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
Via Benzinga
Weight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst
Via Benzinga
Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides
Via Investor's Business Daily
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Pfizer’s Stock Is Down 44% YTD As Woes Continue
Via Talk Markets
1 Underrated Reason to Buy Eli Lilly Stock
Via The Motley Fool
Novo Nordisk Sues Florida Compounding Pharmacies Over Impurities In Products Claiming To Contain Wegovy Ingredient
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?
Via The Motley Fool
Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030
Via SBWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.